Statements (117)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:DNA
gptkb:protein |
| gptkbp:administered_by |
hospital settings
outpatient settings intravenous injection home care settings patients with hemophilia B bleeding episodes adults with hemophilia B preventing bleeding during surgery children with hemophilia B |
| gptkbp:approves |
gptkb:1997
gptkb:2000 gptkb:FDA |
| gptkbp:availability |
widely available in developed countries
limited in developing countries |
| gptkbp:available_on |
single-use vials
|
| gptkbp:average_temperature |
2 to 8 degrees Celsius
|
| gptkbp:benefits |
higher cost
lower risk of viral transmission |
| gptkbp:brand |
Bene FIX
|
| gptkbp:can_be_stored_at |
2-8 degrees Celsius
|
| gptkbp:clinical_trial |
Phase III
ongoing studies efficacy studies long-term safety studies |
| gptkbp:clinical_use |
preventing bleeding episodes
treating bleeding episodes |
| gptkbp:compatibility |
certain blood types
|
| gptkbp:condition |
gptkb:von_Willebrand_disease
acquired hemophilia |
| gptkbp:developed_by |
biotechnology companies
human factor IX gene human factor VIII gene |
| gptkbp:financial_stability |
requires refrigeration
sucrose |
| gptkbp:form |
gptkb:Software_Solutions
lyophilized powder |
| gptkbp:function |
promotes blood clotting
|
| https://www.w3.org/2000/01/rdf-schema#label |
recombinant factor VIII
|
| gptkbp:interacts_with |
antibiotics
other anticoagulants non-steroidal anti-inflammatory drugs |
| gptkbp:involved_in |
blood coagulation
|
| gptkbp:is |
a cure for hemophilia B
|
| gptkbp:is_analyzed_in |
gene therapy approaches
|
| gptkbp:is_associated_with |
improved quality of life
|
| gptkbp:is_available_in |
lyophilized form
|
| gptkbp:is_compared_to |
plasma-derived factor VIII
other clotting factors plasma-derived factor IX |
| gptkbp:is_considered |
a safe treatment option
a biologic drug a first-line therapy a life-saving treatment an effective treatment option |
| gptkbp:is_evaluated_by |
clinical trials
long-term safety |
| gptkbp:is_monitored_by |
factor IX levels
factor VIII levels |
| gptkbp:is_part_of |
patient education programs
multidisciplinary care teams patient management strategies replacement therapy emergency treatment protocols clinical guidelines for hemophilia B comprehensive care for hemophilia hemophilia treatment protocols hemophilia treatment regimen |
| gptkbp:is_protected_by |
surgical bleeding
|
| gptkbp:is_subject_to |
regulatory approval
post-marketing surveillance |
| gptkbp:is_used_for |
preventing joint damage
|
| gptkbp:is_used_in |
gptkb:guidelines
prophylactic treatment emergency care for hemophilia patients sports medicine for hemophilia patients |
| gptkbp:lifespan |
12 hours
|
| gptkbp:marketed_as |
gptkb:Kogenate
Xyntha Advate |
| gptkbp:mechanism_of_action |
activates factor X
|
| gptkbp:patient_education |
emergency protocols
proper storage techniques importance of adherence recognizing bleeding symptoms self-administration training |
| gptkbp:patient_population |
children and adults
|
| gptkbp:price |
high
|
| gptkbp:produced_by |
recombinant DNA technology
genetically modified cells |
| gptkbp:produces |
recombinant DNA technology
|
| gptkbp:provides_guidance_on |
gptkb:World_Federation_of_Hemophilia
gptkb:American_Society_of_Hematology |
| gptkbp:regulatory_compliance |
prescription medication
|
| gptkbp:research_focus |
gptkb:gene_therapy
immunogenicity |
| gptkbp:service_frequency |
every 48 hours
|
| gptkbp:side_effect |
allergic reactions
thromboembolic events inhibitor development |
| gptkbp:suitable_for |
patients with factor IX inhibitors
|
| gptkbp:supply_chain |
cold chain logistics
|
| gptkbp:target_audience |
patients with hemophilia A
|
| gptkbp:treatment |
improved quality of life
increased physical activity enhanced treatment adherence decreased hospitalizations reduced bleeding frequency |
| gptkbp:used_for |
treatment of hemophilia B
|
| gptkbp:used_in |
hemophilia A treatment
|
| gptkbp:weight |
approximately 50 k Da
approximately 300 k Da |
| gptkbp:bfsParent |
gptkb:Alprolix
gptkb:Adynovate gptkb:Kogenate |
| gptkbp:bfsLayer |
6
|